Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | RARG | P13631 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339746 | 0.84 | KCNH2 (0.44) | NPC1ATMMAPTALDH1A1 | |
| SCHEMBL3334100 | 0.83 | RARG (0.37) | RARGBACE1ATMMAPTALDH1A1 | |
| SCHEMBL3639108 | 0.81 | PPARD (0.51) | RARGPPARGALDH1A1 | |
| SCHEMBL3335702 | 0.79 | ATM (0.46) | SMN1; SMN2CSNK2A1RARGHPGDNPC1 | |
| SCHEMBL5759322 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2GLACSNK2A1PPARGHPGD | |
| SCHEMBL3335173 | 0.77 | LMNA (0.48) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL16954839 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2GLACSNK2A1HPGDNPC1 | |
| SCHEMBL7611761 | 0.77 | MEN1 (0.53) | SMN1; SMN2ATMMAPTALDH1A1 | |
| SCHEMBL5146702 | 0.77 | SMN1; SMN2 (0.71) | SMN1; SMN2GLACSNK2A1PPARGHPGD | |
| SCHEMBL8767566 | 0.76 | RARG (0.39) | SMN1; SMN2RARGHPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404836-B2 | 3-phenyl acrylic acid compound activators of type PPAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-03-26 | — | — | US | disclosed |
| US-20100144884-A1 | NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-2164827-A2 | NOVEL DERIVATIVES OF 3-PHENYL ACRYLIC ACID ACTIVATING PPAR-TYPE RECEPTORS, METHOD FOR PREPARING SAME AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development (FR) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008152334-A2 | NOVEL DERIVATIVES OF 3-PHENYL ACRYLIC ACID ACTIVATING PPAR-TYPE RECEPTORS, METHOD FOR PREPARING SAME AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144884-A1 | NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | PPARG, PPARA, PPARD | SMN1; SMN2 4793/4885GLA 1585/4885CSNK2A1 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.